Poly(ethylene glycol)/poly(2-acrylamido-2-methyl-1-propane sulfonic acid) gel electrolytes: a detailed investigation of their conductivity and characterization

Poly(ethylene glycol)/poly(2-acrylamido-2-methyl-1-propane sulfonic acid) (PEG/PAMPS) with a transparent appearance were prepared in the presence of ammonium persulfate (APS) as an initiator at 70 degrees C for 24 h. PEG/PAMPS-based polymer gel electrolytes in a motionless and uniform state were obtained by adding the required amount of liquid electrolytes to a dry PEG/PAMPS polymer. Liquid electrolytes include organic solvents with high boiling points (-1-methyl-2-pyrrolidone (NMP) and gamma-butyrolactone (GBL)) and a redox couple (alkali metal iodide salt/iodine). The optimized conditions for PEG/PAMPS-based gel electrolytes based on the salt type, the concentration of alkali metal iodide salt/iodine, and solvent volume ratio were determined to be NaI, 0.4 M NaI/0.04 M I-2, and NMP:GBL (7:3, v/v), respectively. The highest ionic conductivity and the liquid electrolyte absorbency were 2.58 mS cm(-1) and 3.6 g g(-1) at 25 degrees C, respectively. The ion transport mechanism in both the polymer gel electrolytes and liquid electrolytes is investigated extensively, and their best fits with respect to the temperature dependence of the ionic conductivity are determined with the Arrhenius equation

Activated phosphoinositide 3-kinase δ syndrome : update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

Background: Activated phosphoinositide-3-kinase d syndrome (APDS) is an inborn error of immunity (IEI) with infection susceptibility and immune dysregulation, clinically overlapping with other conditions. Management depends on disease evolution, but predictors of severe disease are lacking. Objectives: This study sought to report the extended spectrum of disease manifestations in APDS1 versus APDS2; compare these to CTLA4 deficiency, NFKB1 deficiency, and STAT3 gain of-function (GOF) disease; and identify predictors of severity in APDS. Methods: Data was collected from the ESID (European Society for Immunodeficiencies)-APDS registry and was compared with published cohorts of the other IEIs. Results: The analysis of 170 patients with APDS outlines high penetrance and early onset of APDS compared to the other IEIs. The large clinical heterogeneity even in individuals with the same PIK3CD variant E1021K illustrates how poorly the genotype predicts the disease phenotype and course. The high clinical overlap between APDS and the other investigated IEIs suggests relevant pathophysiological convergence of the affected pathways. Preferentially affected organ systems indicate specific pathophysiology: bronchiectasis is typical of APDS1; interstitial lung disease and enteropathy are more common in STAT3 GOF and CTLA4 deficiency. Endocrinopathies are most frequent in STAT3 GOF, but growth impairment is also common, particularly in APDS2. Early clinical presentation is a risk factor for severe disease in APDS. Conclusions: APDS illustrates how a single genetic variant can result in a diverse autoimmune-lymphoproliferative phenotype. Overlap with other IEIs is substantial. Some specific features distinguish APDS1 from APDS2. Early onset is a risk factor for severe disease course calling for specific treatment studies in younger patients. (J Allergy Clin Immunol 2023;152:984-96.